Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.

Lawrence R Boone1

  • 1GlaxoSmithKline, Discovery Virology, Research Triangle Park, NC 27709, USA. larry.r.boone@gsk.com

Current Opinion in Investigational Drugs (London, England : 2000)
|February 28, 2006
PubMed
Summary

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are advancing, with TMC-125 and TMC-278 showing promise for treatment-experienced patients. BILR-355 BS is in early trials, while others face discontinuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiretroviral drug development for HIV: challenges for the future.

Current opinion in investigational drugs (London, England : 2000)·2010
Same author

Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.

Journal of medicinal chemistry·2006
Same author

Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.

Antimicrobial agents and chemotherapy·2005
Same author

Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.

Antimicrobial agents and chemotherapy·2005
Same author

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.

Journal of medicinal chemistry·2004
Same author

Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Journal of medicinal chemistry·2004

Area of Science:

  • Virology
  • Pharmacology
  • Drug Development

Background:

  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are crucial in HIV-1 treatment.
  • There is a need for novel NNRTIs effective against resistant strains and suitable for experienced patients.

Purpose of the Study:

  • To review desired attributes for next-generation HIV-1 NNRTIs.
  • To highlight properties of NNRTIs in clinical development.

Main Methods:

  • Review of clinical trial data and compound properties.
  • Analysis of efficacy, safety, and pharmacokinetic profiles.

Main Results:

  • TMC-125 is in Phase III, potentially the first NNRTI for NNRTI-experienced patients.
  • TMC-278 (Phase II) shows higher potency and once-daily dosing suitability.

Related Experiment Videos

  • BILR-355 BS (early Phase II) requires ritonavir boosting and has limited activity against resistant strains.
  • Capravirine and GW-695634 development discontinued due to efficacy and safety concerns.

    • Conclusions:

    • TMC-125 and TMC-278 represent significant advancements in NNRTI development.
    • Ongoing research focuses on overcoming resistance and improving patient outcomes in HIV-1 therapy.